6.11 USD
-0.09 (-1.45%)
6.11 USD
0 (0%)
Overall PBYI gets a fundamental rating of 5 out of 10. We evaluated PBYI against 528 industry peers in the Biotechnology industry. While PBYI has a great profitability rating, there are some minor concerns on its financial health. PBYI has a bad growth rate and is valued cheaply. These ratings could make PBYI a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year PBYI was profitable.
In the past year PBYI had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PBYI reported negative net income in multiple years.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 18.23%, PBYI belongs to the top of the industry, outperforming 96.60% of the companies in the same industry.
PBYI's Return On Equity of 32.08% is amongst the best of the industry. PBYI outperforms 97.92% of its industry peers.
PBYI has a Return On Invested Capital of 22.07%. This is amongst the best in the industry. PBYI outperforms 98.11% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PBYI is in line with the industry average of 18.28%.
The 3 year average ROIC (17.97%) for PBYI is below the current ROIC(22.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.23% | ||
| ROE | 32.08% | ||
| ROIC | 22.07% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
1.3 Margins
PBYI has a better Profit Margin (17.44%) than 93.02% of its industry peers.
Looking at the Operating Margin, with a value of 15.83%, PBYI belongs to the top of the industry, outperforming 93.40% of the companies in the same industry.
PBYI's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 76.91%, PBYI belongs to the best of the industry, outperforming 84.53% of the companies in the same industry.
In the last couple of years the Gross Margin of PBYI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.83% | ||
| PM (TTM) | 17.44% | ||
| GM | 76.91% |
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
2. Health
2.1 Basic Checks
PBYI has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PBYI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PBYI has been increased compared to 5 years ago.
The debt/assets ratio for PBYI has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.89, we must say that PBYI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.89, PBYI is doing worse than 61.32% of the companies in the same industry.
PBYI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.79 | ||
| Altman-Z | -4.89 |
ROIC/WACC2.28
WACC9.68%
2.3 Liquidity
PBYI has a Current Ratio of 1.74. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
PBYI has a Current ratio of 1.74. This is in the lower half of the industry: PBYI underperforms 78.30% of its industry peers.
A Quick Ratio of 1.62 indicates that PBYI should not have too much problems paying its short term obligations.
PBYI has a Quick ratio of 1.62. This is in the lower half of the industry: PBYI underperforms 78.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.74 | ||
| Quick Ratio | 1.62 |
3. Growth
3.1 Past
PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.17%, which is quite impressive.
PBYI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.96%.
PBYI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.28% yearly.
EPS 1Y (TTM)54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.54%
Revenue 1Y (TTM)-12.96%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%-32.3%
3.2 Future
PBYI is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.11% yearly.
Based on estimates for the next years, PBYI will show a decrease in Revenue. The Revenue will decrease by -0.63% on average per year.
EPS Next Y-8.37%
EPS Next 2Y-13.3%
EPS Next 3Y-4.25%
EPS Next 5Y-5.11%
Revenue Next Year-0.97%
Revenue Next 2Y-0.77%
Revenue Next 3Y-0.36%
Revenue Next 5Y-0.63%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.26 indicates a reasonable valuation of PBYI.
Based on the Price/Earnings ratio, PBYI is valued cheaply inside the industry as 98.11% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.19. PBYI is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 13.33, the valuation of PBYI can be described as correct.
Based on the Price/Forward Earnings ratio, PBYI is valued cheaper than 96.60% of the companies in the same industry.
PBYI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 13.33 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBYI is valued cheaply inside the industry as 99.06% of the companies are valued more expensively.
99.81% of the companies in the same industry are more expensive than PBYI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.18 | ||
| EV/EBITDA | 4.62 |
4.3 Compensation for Growth
PBYI has a very decent profitability rating, which may justify a higher PE ratio.
PBYI's earnings are expected to decrease with -4.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.3%
EPS Next 3Y-4.25%
5. Dividend
5.1 Amount
No dividends for PBYI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.11
-0.09 (-1.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.41%
Inst Owner Change-0.19%
Ins Owners15.12%
Ins Owner Change-0.78%
Market Cap307.88M
Revenue(TTM)212.00M
Net Income(TTM)36.98M
Analysts42.86
Price Target4.76 (-22.09%)
Short Float %8.03%
Short Ratio6.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)142.48%
Min EPS beat(2)14.59%
Max EPS beat(2)270.37%
EPS beat(4)4
Avg EPS beat(4)237.87%
Min EPS beat(4)14.59%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)129.74%
EPS beat(12)10
Avg EPS beat(12)120.97%
EPS beat(16)14
Avg EPS beat(16)232.31%
Revenue beat(2)2
Avg Revenue beat(2)3%
Min Revenue beat(2)1.23%
Max Revenue beat(2)4.77%
Revenue beat(4)4
Avg Revenue beat(4)4.4%
Min Revenue beat(4)1.23%
Max Revenue beat(4)10.36%
Revenue beat(8)7
Avg Revenue beat(8)4.18%
Revenue beat(12)10
Avg Revenue beat(12)4.08%
Revenue beat(16)13
Avg Revenue beat(16)5.33%
PT rev (1m)0%
PT rev (3m)7.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.87%
EPS NY rev (1m)0%
EPS NY rev (3m)10.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 13.33 | ||
| P/S | 1.45 | ||
| P/FCF | 7.18 | ||
| P/OCF | 7.16 | ||
| P/B | 2.67 | ||
| P/tB | 4.31 | ||
| EV/EBITDA | 4.62 |
EPS(TTM)0.74
EY12.11%
EPS(NY)0.46
Fwd EY7.5%
FCF(TTM)0.85
FCFY13.92%
OCF(TTM)0.85
OCFY13.96%
SpS4.21
BVpS2.29
TBVpS1.42
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.23% | ||
| ROE | 32.08% | ||
| ROCE | 27.93% | ||
| ROIC | 22.07% | ||
| ROICexc | 102.97% | ||
| ROICexgc | N/A | ||
| OM | 15.83% | ||
| PM (TTM) | 17.44% | ||
| GM | 76.91% | ||
| FCFM | 20.22% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score7
Asset Turnover1.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.79 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.11% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | 4.71 | ||
| Cash Conversion | 96.22% | ||
| Profit Quality | 115.93% | ||
| Current Ratio | 1.74 | ||
| Quick Ratio | 1.62 | ||
| Altman-Z | -4.89 |
F-Score7
WACC9.68%
ROIC/WACC2.28
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.54%
EPS Next Y-8.37%
EPS Next 2Y-13.3%
EPS Next 3Y-4.25%
EPS Next 5Y-5.11%
Revenue 1Y (TTM)-12.96%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%-32.3%
Revenue Next Year-0.97%
Revenue Next 2Y-0.77%
Revenue Next 3Y-0.36%
Revenue Next 5Y-0.63%
EBIT growth 1Y3.58%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year93.13%
EBIT Next 3Y23.6%
EBIT Next 5YN/A
FCF growth 1Y825.85%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y77.42%
OCF growth 3Y23.52%
OCF growth 5Y11.7%
PUMA BIOTECHNOLOGY INC / PBYI FAQ
Can you provide the ChartMill fundamental rating for PUMA BIOTECHNOLOGY INC?
ChartMill assigns a fundamental rating of 5 / 10 to PBYI.
What is the valuation status of PUMA BIOTECHNOLOGY INC (PBYI) stock?
ChartMill assigns a valuation rating of 7 / 10 to PUMA BIOTECHNOLOGY INC (PBYI). This can be considered as Undervalued.
What is the profitability of PBYI stock?
PUMA BIOTECHNOLOGY INC (PBYI) has a profitability rating of 7 / 10.
Can you provide the financial health for PBYI stock?
The financial health rating of PUMA BIOTECHNOLOGY INC (PBYI) is 5 / 10.